pf-573228 Search Results


pf 573228  (MedChemExpress)
95
MedChemExpress pf 573228
Pf 573228, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pf 573228/product/MedChemExpress
Average 95 stars, based on 1 article reviews
pf 573228 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
ion channels  (Tocris)
94
Tocris ion channels
Ion Channels, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ion channels/product/Tocris
Average 94 stars, based on 1 article reviews
ion channels - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
fak inhibitor pf573228  (Selleck Chemicals)
95
Selleck Chemicals fak inhibitor pf573228
Fak Inhibitor Pf573228, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fak inhibitor pf573228/product/Selleck Chemicals
Average 95 stars, based on 1 article reviews
fak inhibitor pf573228 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
pf573228  (TargetMol)
91
TargetMol pf573228
Pf573228, supplied by TargetMol, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pf573228/product/TargetMol
Average 91 stars, based on 1 article reviews
pf573228 - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier
fak inhibitor pf573228  (Tocris)
95
Tocris fak inhibitor pf573228
(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor <t>PF573228,</t> the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.
Fak Inhibitor Pf573228, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fak inhibitor pf573228/product/Tocris
Average 95 stars, based on 1 article reviews
fak inhibitor pf573228 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
small molecule fak inhibitor pf573228  (Pfizer Inc)
90
Pfizer Inc small molecule fak inhibitor pf573228
(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor <t>PF573228,</t> the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.
Small Molecule Fak Inhibitor Pf573228, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small molecule fak inhibitor pf573228/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
small molecule fak inhibitor pf573228 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
fak inhibitors pf-562271  (ApexBio)
90
ApexBio fak inhibitors pf-562271
(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor <t>PF573228,</t> the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.
Fak Inhibitors Pf 562271, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fak inhibitors pf-562271/product/ApexBio
Average 90 stars, based on 1 article reviews
fak inhibitors pf-562271 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
fak inhibitor pf- 573228  (ChemScene llc)
90
ChemScene llc fak inhibitor pf- 573228
(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor <t>PF573228,</t> the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.
Fak Inhibitor Pf 573228, supplied by ChemScene llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fak inhibitor pf- 573228/product/ChemScene llc
Average 90 stars, based on 1 article reviews
fak inhibitor pf- 573228 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
emd57970  (Merck KGaA)
90
Merck KGaA emd57970
(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor <t>PF573228,</t> the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.
Emd57970, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/emd57970/product/Merck KGaA
Average 90 stars, based on 1 article reviews
emd57970 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
pf-573228  (Topscience Co Ltd)
90
Topscience Co Ltd pf-573228
(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor <t>PF573228,</t> the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.
Pf 573228, supplied by Topscience Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pf-573228/product/Topscience Co Ltd
Average 90 stars, based on 1 article reviews
pf-573228 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
p-fak inhibitor pf-573228  (Beyotime)
90
Beyotime p-fak inhibitor pf-573228
(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor <t>PF573228,</t> the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.
P Fak Inhibitor Pf 573228, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p-fak inhibitor pf-573228/product/Beyotime
Average 90 stars, based on 1 article reviews
p-fak inhibitor pf-573228 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
fak inhibitor pf573228  (Absource Diagnostics GmbH)
90
Absource Diagnostics GmbH fak inhibitor pf573228
(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor <t>PF573228,</t> the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.
Fak Inhibitor Pf573228, supplied by Absource Diagnostics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fak inhibitor pf573228/product/Absource Diagnostics GmbH
Average 90 stars, based on 1 article reviews
fak inhibitor pf573228 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


(A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor PF573228, the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.

Journal: Oncogene

Article Title: Integrin β5 contributes to the tumorigenic potential of breast cancer cells through Src-FAK and MEK-ERK signaling pathways

doi: 10.1038/onc.2012.320

Figure Lengend Snippet: (A) Anchorage-independent growth analysis of MDA-MB-231 cells treated with the FAK inhibitor PF573228, the Src inhibitor Dasatinib, or the MEK inhibitor U0126 at the indicated concentration. Statistical analysis by Student t -Test is provided (* p < 0.05; ** p <0.001). (B) MDA-MB-231 cells were treated with the FAK inhibitor PF573228 or the MEK inhibitor U0126 for 24h at the indicated concentrations. Immunoblotting was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, ERK1/2, and phospho-ERK1/2. (C) Immunoblot analysis of whole-cell protein extracts from control and siRNA to FAK treated MDA-MB-231 cells that were treated with 2ng/ml TGF-β1 for 2h and 24h. Membranes were probed with antibodies for FAK, phospho-Smad2, Smad2, phospho-ERK1/2, and GAPDH as loading control. (D) MDA-MB-231 cells were treated with the Src inhibitor Dasatinib at 100nM for the indicated times. Immunoblot analysis was performed on whole-cell extracts probing for FAK, phospho-FAK-Tyr397, phospho-FAK-Tyr861, phospho-FAK-Tyr925, phospho-paxillin-Tyr31, paxillin, ERK1/2, phospho-ERK1/2 and α-tubulin.

Article Snippet: The FAK inhibitor PF573228 was from Tocris (Ellisville, MO); U0126 and AG1478 were from EMD Bioscience-Calbiochem (La Jolla, CA); Dasatinib was a gift of Dr. Yahao Bu (Kinex Pharmaceutical, Buffalo, NY).

Techniques: Concentration Assay, Western Blot, Control